Aims: A second iteration of a sirolimus-eluting stent (SES) that has a biodegradable PLGA polymer coating with an electrografting base layer on a thin-strut (80 µm) cobalt-chromium platform (BuMA Supreme; SINOMED, Tianjin, China) has been developed. This first-in-man trial aimed to assess the efficacy and safety of the novel device.
Introduction
Second-generation drug-eluting stents (DES) have been developed with more biocompatible durable polymer coatings on thinstrut stents and have demonstrated improved safety relative to first-generation DES [1] [2] [3] . Biodegradable polymer (BP)-DES were developed to reduce long-term polymer-related adverse effects 4 .
Several studies have shown improvement of clinical outcomes with BP-DES as compared to durable polymer DES 4 .
The BuMA™ Supreme (SINOMED, Tianjin, China) sirolimuseluting stent (SES) consists of a thin-strut cobalt-chromium platform (80 µm) with a thin (200 nm) electrografted base layer, to which a biodegradable top coat is firmly adhered. The base layer is bonded to the stent surface and both anchors and aligns the molecule of the biodegradable top layer. This prevents the bioactive coating from cracking and delamination upon delivery and expansion of the stent (Figure 1) . The BuMA Supreme SES has a pharmacokinetic polymer degradation/drug release profile where the top coat releases the drug relatively rapidly such that sirolimus release from the stent surface is nearly complete by 28 days after implantation. Less than 1 ng/mg of the drug is maintained in the arterial wall at 60 days after implantation (Figure 2) . Several studies in humans and animal models have demonstrated the efficacy and safety of its predecessor, the BuMA stent, which used a stainless steel platform of 100 µm 5 .
The present first-in-man study assessed nine-month angiographic and 12-month clinical endpoints to evaluate the efficacy and safety of the BuMA Supreme SES versus a durable BioLinx™ (Medtronic, Santa Rosa, CA, USA) tripolymer-coated
Figure 1. The BuMA Supreme stent design. A) Electrografting coating technology (eG): polymer chains (200 nm) of poly n-butyl methacrylate covalently bound by electrografting to an electronically polished thin-strut (80 µm) cobalt-chromium stent platform. B) Link between cells. C) Electron microscopy (×4,500) showing strut of BuMA Supreme (left), electrografted base layer (eG) (mid) and polymer matrix of PLGA containing sirolimus.
(Resolute-type) zotarolimus-eluting stent (ZES). The latter device has shown favourable outcomes in randomised trials 6, 7 .
Methods STUDY DESIGN AND POPULATION
The PIONEER trial is a multicentre, single-blinded, two-arm 1:1 randomised trial, which was designed to demonstrate non-inferiority of the BuMA Supreme SES versus a Resolute-type ZES in terms of nine-month angiographic in-stent late lumen loss (LLL). In addition, secondary clinical endpoints were assessed at 12-month follow-up. Patients were eligible for study enrolment if they met eligibility criteria, the details of which are listed in the Supplementary Appendix. Briefly, patients who presented with stable or unstable angina or silent ischaemia with one or two separate, de novo target lesions in a reference vessel of 2.5-4.5 mm were enrolled in the current trial. Patients with evolving myocardial infarction, bifurcated target lesion, target lesion in left main artery, aorto-ostial target lesion and restenotic target lesion were not eligible for the current trial.
The PIONEER study complied with the Declaration of Helsinki, medical ethics committees at each participating institution approved the trial, and all patients provided written informed consent.
STUDY DEVICES AND IMPLANTATION PROCEDURE
The BuMA Supreme SES is a DES with a rapid exchange balloon-expandable catheter delivery system. The device consists of an extremely thin (200 nm) electrografted (eG) base layer of poly(nbutyl methacrylate) (PBMA), perpendicularly and covalently bound to an electronically polished thin-strut (80 µm) cobalt-chromium stent platform. The base layer forms a thin brush that interdigitates with a 3.8-10 μm-thin top layer -a blend of a biodegradable polylactide-co-glycolic acid (PLGA) polymer and the drug sirolimus (drug concentration: 120 µg/cm² of stent surface). The PLGA polymer layer is designed to resorb in six weeks (Figure 1 . Interventional procedure was performed and dual antiplatelet therapy was administered according to current clinical guidelines.
ENDPOINTS
The primary study endpoint was in-stent LLL at nine months after stent implantation, as assessed by off-line quantitative coronary angiography (QCA) in at least two paired matched views. Secondary angiographic endpoints included acute lumen gain, insegment LLL at nine months, minimum lumen diameter post procedure and at nine months, percent diameter stenosis (DS) post procedure and at nine months, and binary restenosis (DS ≥50%) at nine months. All measurements were performed in-stent, in-segment, and on the 5 mm proximal and distal stent margins.
Secondary clinical endpoints included: 1) acute device success, 2) procedural success, and 3) a device-oriented composite endpoint (DoCE), defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and clinically indicated target lesion revascularisation (CI-TLR). Each definition is described in the Supplementary Appendix. Stent thrombosis was defined according to Academic Research Consortium (ARC) definitions 12 and was assessed as a secondary endpoint. MI was defined according to the criteria of the third universal definition 13 except for MI type 4a (periprocedural MI), for which the SCAI definition 14 was used.
An independent clinical events committee adjudicated the clinical endpoints; an independent data safety monitoring board supervised the trial. Angiographic follow-up was performed at nine months. Patients were clinically followed at 1, 9, and 12 months. 
PIONEER trial
The trial was monitored by an independent clinical research organisation (Cardialysis, Rotterdam, the Netherlands).
QUANTITATIVE CORONARY ANGIOGRAPHY ANALYSIS
Off-line QCA analysis was performed by an independent core laboratory (Cardialysis, Rotterdam, the Netherlands) using the CAAS system (Pie Medical Imaging, Maastricht, the Netherlands) according to standard protocols. If the target lesion was revascularised at any time between baseline and nine months, the prerevascularisation angiogram was analysed. In-segment late lumen loss (mm) Figure 4) , which means that non-inferiority was not met. Nevertheless, this did not translate into a significant difference in the rates of in-stent or in-segment binary restenosis ( Figure 5 ).
STATISTICAL ANALYSIS

PIONEER trial 170 patients randomised Intention-to-treat analysis
TWELVE-MONTH CLINICAL OUTCOMES
The 12-month clinical follow-up was available for 82 (98.8%) patients of the SES group and 87 (100%) patients in the Resolutetype ZES group (Figure 3) . (Table 3) .
Discussion
The main findings of the PIONEER trial are the following: 1) the criterion for non-inferiority of the primary angiographic endpoint (in-stent LLL) was not met; 2) nevertheless, in-stent and in-segment %DS as well as the binary restenosis rate did not differ significantly between stent groups; and 3) the rates of the DoCE were similar in both treatment arms. In-stent diameter stenosis (%) 
PIONEER trial
Stent thrombosis
Definite or probable stent thrombosis 0 (0) 0 (0) 0.0% NA Data are expressed as n (%). Analyses were performed based on the principle of intention-to-treat. # One patient in SES group refused 12-month follow-up. *Defined according to SCAI definition 11 . **Defined according to third universal definition 10 .
¶ One TLR in the SES group and three TLRs in the ZES group were adjudicated as "non-clinically indicated TLR" due to the absence of symptom or functional assessment. DoCE: device-oriented composite endpoint; MI: myocardial infarction; NA: not available; TLR: target lesion revascularisation; TV-MI: target vessel myocardial infarction; TVR: target vessel revascularisation
LATE LUMEN LOSS
In the present trial, the LLL of the BuMA Supreme SES (0.29±0.33 mm) was numerically larger than anticipated based on the previous study of its predecessor (0.24±0.33 mm) 15 . Reasons for this discrepancy could reside in differences in study background (e.g., patients, lesion types, lesion length, procedural characteristics such as the degree of acute gain and residual stenosis) and in dissimilar methodologies of the angiographic core laboratories. Moreover, the LLL in the Resolute-type ZES group of the present trial (0.14±0.37 mm) was lower than the LLL observed in the Resolute first-in-man (FIM) trial (0.22±0.27 mm) which, in addition, was analysed by another core lab using a different methodology 16 . It might be related to differences in baseline procedure. Acute gain (in-stent) of Resolute ZES in the current trial was lower than the one in the Resolute FIM trial (1.46±0.64 mm vs. 1.93±0.45 mm), whereas residual percent stenosis in the Resolute ZES group in the current trial was greater than the one in the Resolute FIM trial (11.3±5.8% vs. 3.36±8.54%). Mauri 17 . The differences in these parameters might be related to the difference in LLL between the two trials.
When PIONEER-like lesions, treated with a Resolute-type ZES, were selected from the Resolute all-comers trial, the angiographic LLL at 13 months, analysed by the core lab of the present study, was 0.19±0.26 mm 7 . Considering this, the relatively low LLL for the second and third iterations of the Resolute ZES may be seen in a different light and are less surprising.
OTHER ANGIOGRAPHIC PARAMETERS AND CLINICAL EFFICACY
Although in the current trial the BuMA Supreme SES did not meet the non-inferiority criterion in in-stent LLL, there was no betweengroup difference in in-segment percent DS (25±13% vs. 24±13%). For both DES groups the in-segment percent DS was within the range of data seen with DES that have recently been approved by the Food and Drug Administration (FDA), as has been reported by the ESC/EAPCI task force on the evaluation of coronary stents in Europe in their executive summary for the European Union 18 . In addition, the 12-month DoCE rates were comparably low for both treatment arms (4.9% vs. 5.7%), and in both treatment arms there was no case of definite or probable stent thrombosis.
THE CLINICAL SIGNIFICANCE OF LLL AND REGULATORY PERSPECTIVE
In the early days of balloon angioplasty, there was no quantitative method to assess the respective contribution of constrictive remodelling and neointimal proliferation. With the advent of quantitative angiography, late lumen loss, defined as a change in minimum lumen diameter between post-procedure and follow-up, was developed as a continuous variable to define restenosis and has for more than a quarter of a century remained the gold standard for regulatory bodies in the assessment of the "antirestenotic" efficacy of coronary devices 19 .
In the bare metal stent era, the LLL in absolute value was paradoxically doubled (0.65±0.57 mm) as compared to balloon angioplasty (0.32±0.47 mm), although minimal lumen diameter, binary restenosis rate, and target lesion revascularisation rate were improved 20 . LLL of a metallic coronary stent reflected exclusively the neointimal proliferation as the stent prevented constrictive vascular remodelling 21 . After the emergence of DES, LLL was reduced to a relatively low value, but the "near eradication" of intra-stent neointima was not per se a criterion of device safety. In the RAVEL trial, the first-generation CYPHER ® (Cordis, Cardinal Health, Milpitas, CA, USA) SES had no LLL at all (-0.01±0.33 mm), but the increase in late and very late adverse events with this type of DES showed clearly that LLL was a rather unsuitable parameter to predict the efficacy and long-term safety of this device 22, 23 . A very low LLL may indeed reflect a delayed and incomplete healing process with uncovered and malapposed struts, only seen on optical coherence tomography (OCT) 24 . Despite these facts, LLL remained a standard measure of the performance of new coronary stents and scaffolds 18 . Angiographic LLL has been used for evaluating the process of neointimal hyperplasia and late constrictive remodelling in clinical trials with balloon angioplasty and stents, because the LLL was considered a robust continuous parameter that required a smaller sample size than the traditional binary restenosis. However, in the current era of DES, the clinical significance of comparing DES with very low LLL is debatable. Pocock et al, in data from a pooled analysis, showed that, within a range of relatively low LLL values (up to 1.0 mm), differences in LLL were not associated with a significant difference in the target lesion revascularisation rate 18, 25 . In contrast, a mild or moderately (certainly not an excessively) increased LLL might be favourable in terms of completeness of stent coverage 24 . The BuMA Supreme stent was designed to elute 92% of the drug in 28 days and leave a drug level in the artery wall 60 days after implantation of less than 1 ng/mg -a concentration that is below the therapeutic level of prevention of neointimal progression, allowing early neointimal coverage (Figure 2 ). In the BuMA-OCT randomised trial at three-month follow-up, the BuMA stent had a more favourable neointimal coverage than the PLA polymer-based EXCEL SES (JW Medical Systems, Weihai, China), which is characterised by drug elution during a much longer period of time (180 days) 8 . The Endeavor ® zotarolimus-eluting stent (E-ZES) (Medtronic) was similarly designed to complete drug elution within two weeks 26 . Interestingly, although E-ZES had a greater in-stent LLL compared to the TAXUS™ paclitaxel-eluting stent (PES) (Boston Scientific, Marlborough, MA, USA) in the ENDEAVOR IV randomised control trial (0.67±0.49 mm vs. 0.42±0.50 mm, p<0.001), E-ZES was non-inferior to PES with rates of target vessel failure 6.6% versus 7.1%, respectively (p non-inferiority <0.001) 27 . It is notable that regulatory bodies in many countries, such as the FDA in the USA, approved the E-ZES holding clinical outcomes in great account.
The ultimate treatment goal of stenting a narrowed coronary segment is to re-establish optimal hyperaemic blood supply to the subtended myocardium, which today can be quantified by a functional test such as fractional flow reserve (FFR). Future trials and PIONEER trial regulatory bodies may embody a combined angiographic and functional approach as criteria for approval. Thus, there is currently a need to establish an optimal parameter to validate stent performance that should precisely reflect improvements in functionality and reductions in adverse clinical event risk.
Limitations
The study was powered for the primary endpoint only; clinical outcomes are only hypothesis-generating. The sample size calculation was based on data of the first-in-man study of the Resolute ZES, which was analysed by a different core laboratory.
Conclusions
The trial did not meet its primary endpoint of non-inferiority in in-stent LLL at nine-month angiographic follow-up. Nevertheless, several other angiographic parameters such as percent diameter stenosis and binary restenosis rate were similar for both stents. One-year clinical event rates, although obtained in a relatively small patient population, were comparably low with both devices. Both this and future trials will further explore whether or not the unique pharmacokinetic properties of this stent impact on long-term outcomes.
Impact on daily practice
Nine months after the implantation of the novel BuMA Supreme sirolimus-eluting stent, the trial did not meet its primary endpoint of non-inferiority in terms of angiographic late lumen loss. Nevertheless, several other angiographic parameters and clinical endpoints were similar to the comparator device, suggesting that, in the current drug-eluting stent era, the clinical significance of the parameter late lumen loss may be limited and that its suitability for predicting the efficacy and safety of novel devices is debatable.
-objective signs of ischaemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel; -abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve).
A TLR with a diameter stenosis ≥70% even in the absence of the above-mentioned ischaemic signs or symptoms is also considered clinically indicated.
Sample size calculation of the PIONEER trial
The trial was powered for testing non-inferiority for the primary endpoint at nine-month angiographic follow-up. An LLL of 0.22 mm was assumed for both device groups, based on the Resolute first-in-human trial [16] , in which the Brigham and Women's Angiographic Core Laboratory in Boston, MA, USA, measured an LLL of 0.22±0.27 mm. The noninferiority margin was set as 0.16 mm, similar to the SPIRIT II trial [28] . Assuming an attrition rate of 10%, 84 patients per arm were required to achieve 95% power to demonstrate non-inferiority with a one-sided type α error of 0.025. Presented number (n) of lesions or patients with available data. † Data were derived from eCRF (SES: N=83, L=95; ZES: N=87, L=91). † † Data were based on core lab analysis with available QCA at pre-procedure (SES: N=81, L=92; ZES: N=83, L=95). 2 lesions in SES: lost film; 5 lesions in ZES: target lesion not recorded; 1 lesion in SES and 1 lesion in ZES: non-analysable due to the presence of a radiopaque marker of guidewire. 
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